CASE REPORT

Novel in-frame deletion in MFSD8 gene revealed by trio whole exome sequencing in an Iranian affected with neuronal ceroid lipofuscinosis type 7: a case report

Ali Hosseini Bereshneh and Masoud Garshasbi*

Abstract

Background: The neuronal ceroid lipofuscinoses are a group of neurodegenerative, lysosomal storage disorders. They are inherited as an autosomal recessive pattern with the exception of adult neuronal ceroid lipofuscinosis, which can be inherited in either an autosomal recessive or an autosomal dominant manner. The neuronal ceroid lipofuscinoses are characterized by accumulation of autofluorescent lipopigments in the cells and one of the most important pathological manifestations is ceroid accumulation in the lysosomes. Various types of neuronal ceroid lipofuscinoses are categorized based on the clinical manifestations and the genes involved. Accumulatively, 15 different genes have been found so far to be implicated in the pathogenesis of at least nine different types of neuronal ceroid lipofuscinoses, which result in similar pathological and clinical manifestations.

Case presentation: A 5-year-old Iranian boy affected by a neurodegenerative disorder with speech problems, lack of concentration, walking disability at age of 4 years leading to quadriplegia, spontaneous laughing, hidden seizure, clumsiness, psychomotor delay, and vision deterioration at age of 5 years, which could be the consequence of macular dystrophy, was referred to us for genetic testing. Trio whole exome sequencing, Sanger validation, and segregation analysis discovered a novel in-frame small deletion c.325_339del (p.Val109_Ile113del) in MFSD8 gene associated with neuronal ceroid lipofuscinosis type 7.

Conclusions: The deletion found in this patient affects the exon 5 of this gene which is the region encoding transmembrane domain. Sequencing analysis in this family has shown that the index is homozygous for 15 base pairs in-frame deletion, his uncle has normal homozygous, and his parents are heterozygous. This pattern of mutation inheritance and the signs and symptoms observed in the affected male of this family are compatible with what is described in the literature for neuronal ceroid lipofuscinosis type 7 and, therefore, suggest that the MFSD8 gene deletion found in this study is most probably the cause of disease in this family.

Keywords: Neuronal ceroid lipofuscinosis type 7, Neurodegenerative, MFSD8 gene

* Correspondence: masoud.garshasbi@modares.ac.ir
Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The neuronal ceroid lipofuscinoses (NCLs or CLNs), also called Batten disease, are a set of neurodegenerative genetic disorders with an overall frequency of 1 in 100,000 individuals around the world [1, 2]. This condition conforms to an autosomal recessive (AR) pattern of inheritance and is mainly caused by consanguineous marriage [3]. Babies affected with these lysosomal storage diseases do not manifest any clinical symptoms at birth; however, signs and symptoms mostly begin before 7 years of age depending on the gene involved [3, 4]. These conditions are genetically heterogeneous and consist of a wide spectrum of phenotypical and clinical manifestations. NCLs are characterized by the accumulation of autofluorescent lipopigments in cells [5] and one of the most important pathological manifestations is ceroid accumulation in lysosomes [1, 6]. The accumulation of storage material in nerve cells results in massive neuronal loss and subsequent apoptosis, as has been shown in an autopsy of the brain [7]. The categorization of various types of NCLs is based on the phenotype and the genes that are mutated. Accumulatively, mutation in at least 15 different genes has been shown to be implicated in the pathogenesis of at least nine different types of NCLs which result in a similar pathological and clinical manifestation; Table 1 [8–10]. Genes involved in the pathogenesis of NCLs are mainly affected by loss-of-function mutations [11, 12].

Phenotypically, there are three common different forms of NCLs; the categorization of these three forms of NCLs is mainly based on the age of onset: infantile NCL (INCL) that begins between 6 and 18 months of age; late INCL (LINCL) which begins at 2–4 years of age; and juvenile NCL (JNCL) which begins at the age of 6–10 years or sometimes in adulthood [13–15]. All types show overlapping sign and symptoms, mainly cognitive impairment, progressive neuronal degeneration, motor deficits, seizures, progressive visual deterioration, and blindness [16]. Motor dysfunction could lead to subsequent quadriplegia [17, 18]. The genes involved in NCLs present similar clinical manifestations; so, the finding of genetic mutations may explain unclear clinical findings and distinguish between them [19, 20].

The most prevalent types of NCLs are NCL1, which is considered an infantile form, NCL2, which is considered a late infantile form, and NCL3, which is considered a juvenile form [21]. NCL1 is the most common form of INCLs. At birth, a baby with NCL1 has normal development, but this process is lost and motor dysfunction leads to hypotonia [22]. There is evident vision loss and seizure at approximately 1 year of age [23]. Profound microcephaly is a usual finding and patients will usually die before they reach the age of 7 years. Mutation in the palmitoyl-protein thioesterase (PPT) gene which encodes a fatty acid cleavage lysosomal protein is the cause of NCL1. R122W (c.364A>T) and R151X (c.451C>T) are the most common mutations of the PTT gene and accounted for approximately 20% of mutations [2]. NCL2, also called Jansky–Bielschowsky disease, in which almost the majority of affected patients' manifestations begin at late infantile period of life, is caused by mutations in the CLN2 gene which encodes tripeptidyl-peptidase 1 (TPP1) [24]. NCL3 is the juvenile form of this

| Types of NCLs | Pattern | Onset | Gene | Chromosome location |
|--------------|---------|-------|------|---------------------|
| NCL1 | AR | Infantile | PTT1/CLN1 | 1p32 |
| NCL2 | AR | Late infantile | TPP1/CLN2 | 11p15.5 |
| NCL3 | | Juvenile | CLN3 | 16p12.1 |
| NCL4 | AR | Adulthood | CLN6 | 15q21-q23 |
| NCL5 | AR | Late infantile | CLN5 | 13q21.1-q32 |
| NCL6 | AR | Late infantile | CLN6 | 15q21.2q23 |
| NCL7 | AR | Late infantile | CLN7/MFSD8 | 4q28.1-q28.2 |
| NCL8 | AR | Late infantile | CLN8 | 8p23.3 |
| NCL9 | AR | Juvenile | Unknown | Unknown |
| NCL10 | AR | Newborn | CLN10/CTSD | 1p15.5 |

AD autosomal dominant, AR autosomal recessive, NCL neuronal ceroid lipofuscinosis
disease and often diagnosed with retinitis pigmentosa and late onset seizures at the second decade of life [25]. There are other various types of NCLs; some of these conform to an autosomal dominant pattern of inheritance (types of NCL4 which are caused by mutation in the DNAJC5 gene). NCL10 is the most malignant form and the only type of NCL which affect newborns [26–28]. NCL7 is caused by mutations in the MFSD8/CLN7 gene and is a LINCL type [27, 28].

**Case presentation**

A 5-year-old Iranian boy with a neurodegenerative disorder was referred for genetic testing. His clinical symptoms were speech problems, lack of concentration, walking disability at age of 4 years leading to quadriplegia, spontaneous laughing and crying because of hidden seizure, clumsiness, psychomotor delay, and vision deterioration at age of 5 years which could be the consequence of macular dystrophy. Brain magnetic resonance imaging
(MRI) and electroencephalogram (EEG) showed bilateral white matter signal change with preservation of white matter (Fig. 1 and Fig. 2). There are no available histopathological studies or skin biopsy for this patient.

The organic acids in his urine were determined using gas chromatography–mass spectrometry (GC–MS) of the trimethylsilyl ethers and esters of the ethyl acetate extract from acidified urine after preparation of the ethoxime derivatives. The organic acid in the urine of this patient showed a normal pattern with no evidence for metabolic disorders. There is no evidence for tyrosinemia, glutaric aciduria, methylmalonic aciduria, Canavan disease, propionic aciduria, isovaleric aciduria, and other organic aciduria known in Iran. Neonatal screening, clinical chemistry, and metabolism assays showed a normal pattern and these analyses were unremarkable (Table 2 and Table 3).

Our patient’s parents are first cousins and had experienced three gestations, the first one aborted spontaneously before 4 weeks of pregnancy. The second one is the male reported here and the third one is a 2-year-old girl who does not manifest any signs and symptoms yet and seems to be normal. The pedigree is shown in Fig. 3.

Deoxyribonucleic acid (DNA) was extracted from peripheral blood of our patient and his healthy parents. Whole exome sequencing (WES) was performed on all three samples as following. Approximately 37 mega base pairs (Mb; 214,405 exons) of the Consensus Coding Sequences (CCS) were enriched from fragmented genomic DNA by > 340,000 probes designed against the human genome (Nextera Rapid Capture Exome, Illumina) and the generated library sequenced on an Illumina HiSeq 4000 platform (Illumina) to an average coverage depth of more than 100 × (Table 4). An end-to-end bioinformatics pipeline including base calling, primary filtering of low quality reads and probable artifacts, and annotation of variants was applied. All disease-causing variants reported in HGMD® or ClinVar (class 1) as well as all variants with minor allele frequency (MAF) of less than 1% in Exome Aggregation Consortium (ExAC) database were considered. The evaluation focused on exons and intron boundaries +/− 20. All relevant inheritance patterns were considered and clinical information was used to evaluate eventually identified variants. Relevant variants identified by WES were validated by Sanger sequencing in forward and reverse direction. By applying different filtering steps mentioned in the method part we ended up with only two novel variants in MFSD8 and AFF2 genes (Table 5).

The c.325_339del (p.Val109_Ile113del) variant in the MFSD8 gene was a previously unreported variant and found to be homozygous in our patient whereas his parents were heterozygote carriers (Table 5). Segregation analysis of this variant was done in the

### Table 2 Neonatal screening

| Assay                        | Result | Reference range |
|------------------------------|--------|-----------------|
| Neonatal screening           |        |                 |
| Thyroid-stimulating hormone (TSH) | < 10 mU/l | < 10 mU/l |
| 17-OH progesterone           | < 5 nmol/l | < 5 nmol/l |
| Galactose (GAL; GAL-1-P)     | < 18 mg/dL | < 18 mg/dL |
| Succinylacetone              | < 5 μmol/l | < 5 μmol/l |
| GAL-1-P uridylytransferase   | > 20% activity | > 20% activity |
| Biotinidase                  | > 30% activity | > 30% activity |
| Disorder of amino acid metabolism |    |                 |
| Amino acids (including phenyl) TMS | Unremarkable |                 |
| Disorders of beta oxidation of fatty acids |    |                 |
| MCADD                        | Unremarkable |                 |
| VLCADD                       | Unremarkable |                 |
| LCHADD                       | Unremarkable |                 |
| Disorders of carnitine metabolism |    |                 |
| Acylcarnitines. TMS         | Unremarkable |                 |
| Disorders of organic acids   |    |                 |
| Isovalerylcarboxylic acid    | Unremarkable |                 |
| Glutaric acid                | Unremarkable |                 |
| Defects of urea cycle        |    |                 |
| Citrulline                   | Unremarkable |                 |
| Argininosuccinate            | Unremarkable |                 |

### Table 3 Clinical chemistry and metabolism assays

| Assay                        | Result | Reference range |
|------------------------------|--------|-----------------|
| Creatinine                   | 0.89 g/l | 0.12–1.12 g/l |
| Docosanoic acid (C22)        | 45.8 nmol/ml | 15–113 nmol/ml |
| Tetracosanoic acid (C24)     | 41.6 nmol/ml | 12–94 nmol/ml |
| Hexacosanoic acid (C26)      | 0.4 nmol/ml | 0.2–1.6 nmol/ml |
| C24/C22                      | 0.91 | 0.55–1.05 |
| C26/C22                      | 0.009 | 0.005–0.029 |
| Phytanic acid                | 3.2 nmol/ml | 0.3–31 nmol/ml |
| Aryl sulfatase A             | 0.808 mu/mg | 0.375–1.815 |
| Aryl sulfatase B             | 1.654 mu/mg | 0.722–3.749 |

act, GAL-1-P galactose-1-phosphate. LCHADD long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, MCADD medium-chain acyl-CoA dehydrogenase deficiency, phenyl phenylalanine, TMS tandem mass spectrometry, VLCADD very long-chain acyl-CoA dehydrogenase deficiency.
affected index, his parents, and relatives. It is a deletion of 15 base pairs (bp), which causes the loss of five residues. The evolutionary conservation of amino acid residues in the region of deletion estimated by ConSurf tool [29] is shown in Fig. 4.

The c.259A>G (p.Asn87Asp) variant found in AFF2 was a hemizygous change in our patient; his mother was also heterozygous whereas his father was negative for this variant. This variant had not been reported in the public databases at the time of this publication (Table 5).

**Discussion**

The identified variant is a 15 bp in-frame deletion in MFSD8 gene. Pathogenic variants in the MFSD8 gene have been shown to be associated with AR NCL type 7. Visual loss and seizures may be the initial signs and symptoms. Epilepsy, ataxia, and myoclonus may be the initial features [28] in children with age of onset after 4 years (Tables 6 and 7). Segregation analysis in this family found 15 bp in-frame deletion in MFSD8 gene which is compatible with disease (Fig. 3).

MFSD8 is located on chromosome 4q28.1-q28.2; it has 55,180 bp and 13 exons, encoding a 4562 bp transcript and a protein with 518 amino acids. Major facilitator superfamily domain-containing protein 8 which encoded by MFSD8 is a transmembrane ubiquitous protein that consists of a major facilitator superfamily (MFS) and transporter domains [27]. This protein locates into lysosomal membrane and acts as a multi-pass membrane protein using chemiosmotic ion gradients [30]. Figure 5 shows topological structure of MFSD8 wild type and mutant protein. The deletion found in this patient affects the exon 5 of this gene which is the region encoding transmembrane domain. According to IRANOME database (http://www.iranome.ir/), the mean allele frequency of this variant is unknown.

Based on the NCL mutation database held at the University College London, at the time of writing this manuscript, there were 38 reported mutations in MFSD8 gene in different populations [9]. The most common mutations are missense and nonsense mutations; however, other types of mutations such as splice site, single bp deletion, frameshift, and one case of 17 bp deletion are also reported [28].

**Table 4** Analysis statistics, average coverage and % target base pairs covered

|          | Average coverage (X) | % target bp covered |
|----------|----------------------|---------------------|
|          | 0X  | ≥ 1X | ≥ 5X | ≥ 10X | ≥ 20X | ≥ 50X |
| Index    | 111.69 | 0.17 | 99.83 | 99.34 | 98.57 | 96.51 | 85.37 |
| Mother   | 101.42 | 0.33 | 99.67 | 98.95 | 97.98 | 95.36 | 82.09 |
| Father   | 106.15 | 0.19 | 99.81 | 99.25 | 98.32 | 95.86 | 83.15 |

bp base pairs
Rare pathogenic variants in the AFF2 gene have been identified in patients with autism and attention deficit hyperactivity disorders as well as with X-linked intellectual disability and developmental and speech delay [31, 32]. In addition, this gene has been associated with syndromic autism, where a subpopulation of individuals with a given syndrome develops autism. A rare pathogenic variant in the AFF2 gene has been identified in patients with fragile X syndrome [32]. Mondal et al. suggested that rare variants in AFF2 may be a cause for previously unrecognized autism spectrum disorder (ASD) susceptibility locus and may help to explain some of the male excess of ASD [33]. The other related phenotypes to AFF2 gene are abnormality of metabolism/homeostasis [34], aggressive behavior [35], epicanthic fold, and delayed speech and development of language [36].

**Table 5** Results of trio whole exome sequencing and significant findings

| Gene (transcript) | Nucleotide (protein) | Zygosity | Described by | In silico parameters* | MAF** | Variant classification*** | Disorder (OMIM# inheritance) |
|-------------------|----------------------|----------|--------------|-----------------------|-------|--------------------------|-----------------------------|
| AFF2 (NM_002025.3) c.259A>G (p.Asn87Asp) | Hem. Het. – | Not described | 2/4 Damaging | Not detected | Significance uncertain (class 3) | AFF2-related X-linked mental retardation (309,548, XLR) |
| MFSD8 (NM_152778.2) c.325_339del (p.Val109_Ile113del) | Hom. Het. Het. | Not described | In-frame small deletion | Not detected | Significance uncertain (class 3) | Neuronal ceroid lipofuscinosis type 7 (610,951, AR) |

* number of in silico prediction programs that predict pathogenicity/all applicable programs (SIFT, PolyPhen-2, AlignGVD, MutationTaster), ** highest minor allele frequency (MAF) of representative population – Exome Aggregation Consortium (ExAC) database, Exome Sequencing Project (ESP), or 1000 Genomes Project (1000G), *** based on ACMG recommendations, ACMG American College of Medical Genetics and Genomics, AR autosomal recessive, hem hemizygous, het heterozygous, hom homozygous, MAF minor allele frequency, OMIM Online Mendelian Inheritance in Man, XLR X-Linked Recessive

**AFF2** is a protein coding gene and member of the **AF4/FMR2** gene family which is located on chromosome Xq28. This ribonucleic acid (RNA)-binding protein is implicated in the splicing process. The trinucleotide repeat expansion of CCG at 5′ untranslated region (UTR) of AFF2 causes fragile XE syndrome (FRAXE) [37]. More details of this gene are included in Tables 6 and 7. Although the hemizygous variant found in the affected male of this family segregates in the tested samples, based on the clinical symptoms of the affected male, this variant cannot explain the hallmark and pathognomonic characteristics observed in the affected male. So, based on the clinical findings, correlation of the AFF2 variant with the disease in this family is very unlikely. Tables 6 and 7 summarize the expected and observed phenotypic symptoms.

---

**Fig. 4** The conservation scale adapted from the ConSurf Service. [http://consurf.tau.ac.il/2016/](http://consurf.tau.ac.il/2016/). Mutated domain highlighted in box
Table 6  **AFF2** and **MFSD8** genes information and aliases

| Gene | Ensembl/OMIM ID/ Gene Ontology/ Location/ Exon count | Function |
|------|------------------------------------------------------|----------|
| MFSD8 (NM_152778.2) | ENSG00000164073/ 611,124/ GO:0007040 GO:0055085 4q28.2/ 13 Exons | Major facilitator superfamily domain-containing 8, CLN7 Transmembrane ubiquitous protein consists of major facilitator superfamily and transporter domains |
| AFF2 (NM_002025.3) | ENSG00000155966/ 300,806/ GO:0002151 Xq28/ 22 Exons | AF4/FMR2 family member 2, fragile X mental retardation syndrome protein, fragile X mental retardation 2 protein, protein FMR-2, FMR2P, FMR2, OX19, fragile X mental retardation 2, AF4/FMR2 family member 2 G-quadruplex RNA binding, RNA splicing |

OMIM Online Mendelian Inheritance in Man
RNA Ribonucleic acid

Table 7  Common reported mutations of **AFF2** and **MFSD8** genes, related signs and symptoms and disorders

| Gene | Common reported mutations | Signs and symptoms | Related disorders |
|------|----------------------------|--------------------|------------------|
| MFSD8 (NM_152778.2) | Missense and nonsense mutation, splice site mutation, frameshift, deletion | Seizures or motor impairment, mental regression, myoclonus seizure, speech impairment, loss of motor function and quadriplegia, early onset loss of vision, sleep disorders, loss of cognitive function | Ceroid lipofuscinosis, neuronal, 7 |
| AFF2 (NM_002025.3) | Triple expansion of GCC to > 200 in comparison with 6–25 normal copy number of GCC | Mild-to-moderate mental retardation, learning disabilities, communication problems, attention loss, hyperactivity, autistic behaviors, metabolic and homeostatic abnormalities | Fragile XE syndrome, X-linked mental retardation associated with fragile site FRAXE, FRAXE intellectual disability |

FRAXE fragile XE syndrome

Fig. 5 Front view and surface of MFSD8 protein. a Normal; b mutant. Structural topology has been changed in mutant form. Adapted from Yet Another Scientific Artificial Reality Application (YASARA)
Conclusions

Sequencing analysis in this family has shown that the index is homozygous for 15 bp in-frame deletion, his uncle has normal homozygous, and his parents are heterozygous (Fig. 6).

This pattern of mutation inheritance and the signs and symptoms observed in the affected male of this family are compatible with what is described in the literature for NCL type 7 and, therefore, suggest that the MFSD8 deletion found in this study is most probably the cause of disease in this family.

Abbreviations

AR: Autosomal recessive; ASD: Autism spectrum disorder; bp: Base pair; CCS: Consensus Coding Sequences; CLNs or NCLs: Neuronal ceroid lipofuscinoses; EEG: Electroencephalogram; FRAXE: Fragile XE syndrome; GC-MS: Gas chromatography–mass spectrometry; INCL: Infantile neuronal ceroid lipofuscinosi; JNCL: Juvenile neuronal ceroid lipofuscinosis; LINCL: Late infantile neuronal ceroid lipofuscinosi; MAF: Minor allele frequency; Mb: Mega base pairs; MFS: Major facilitator superfamily; NCLs or CLNs: Neuronal ceroid lipofuscinoses; PPT: Palmitoyl-protein thioesterase; TPP1: Tripeptidyl-peptidase 1; UTR: Untranslated region; WES: Whole exome sequencing

Acknowledgements

The Authors would like to give special thanks to the involved family who tightly collaborated with this report.

We are also grateful to Dr Ahmad Reza Salehi and Mr Ehsan Razmara for their assistance and valuable comments.

Availability of data and materials

Results of genetic analysis are included in this report.

Authors’ contributions

MG conducted the experiments. MG and AHB analysed the data. AHB contributed reagents/materials/analysis tools. MG and AHB wrote the paper. MG and AHB read and approved the final manuscript.

Ethics approval and consent to participate

The involved family was informed about the benefits and consequence of genetics testing and a written consent letter was also obtained for their participation.

Consent for publication

Written informed consent was obtained from the patient’s legal guardian(s) for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
1. Geraerts RD, Koh SY, Hastings ML, Kielian T, Pearce DA, Weiner JM. Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis. Orphanet J Rare Dis. 2016;11(1):40.

2. Bennett MJ, Rakheja D. The neuronal ceroid-lipofuscinoses. Dev. Disabil. Res. Rev. 2013;17(3):254–9.

3. Jadav RH, Sinha S, Yashu TC, Aravintha H, Gayathri N, Rao S, Bindu PS, Sathishchandra P. Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes. Pediatr Neurol. 2014;50(1):85–95.

4. Albert D, De Los RE, Vidaurre J. A case of neuronal Ceroid Lipofuscinosis masquerading as Panayotopoulos syndrome. J Pediatr Epilepsy. 2016;5(01): 047–52.

5. Stogmann E, El Tawil S, Wagenstaller J, Gaber A, Edris S, Abdelhady A, Assem-Hilger E, Leutmezer F, Bonelli S, Baumgartner C, Zimprich F. A novel mutation in the MFSD8 gene in late infantile neuronal ceroid lipofuscinosis. Neurogenetics. 2009;10(1):73–7.

6. Mink JW, Augustine EF, Adams HR, Marshall FJ, Ivory JM. Classification and natural history of the neuronal ceroid lipofuscinoses. J Child Neurol. 2013;9:0883073813494268.

7. Halita M, Goebel HH. The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim Biophys Acta. 2013;1832(11):1795–800.

8. Goebel HH, Mole SE, Lake BD. The neuronal ceroid lipofuscinoses (Batten disease). Amsterdam: IOS Press; 1999.

9. NCL mutation database. Available at: https://www.ucl.ac.uk/ncl/SummaryTableMay2015.htm.

10. Warrier V, Veira M, Mole SE. Genetic basis and phenotypic correlations of the neuronal ceroid lipofuscinoses. Biochim Biophys Acta. 2013;1832(11):1827–30.

11. Sleat DE, Gin RM, Sohar I, Wisniewski K, Silvower-Brooks S, Pullarkat RK, Palmer DN, Lerner TJ, Boustany RM, Uldall P, Skakotans AM. Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. Am J Hum Genet. 1999;64(6):1511–23.

12. Mole SE, Williams RE, Goebel HH. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics. 2005;63(1):107–26.

13. Jalanko A, Braulke T. Neuronal ceroid lipofuscinoses. Neurogenetics. 2005;6(3):107.

14. Giddon ME. Excess variants in chromosome 1. Genomics. 1991;9(33):1802–5.

15. Mahmood F, Su F, Cooke J, Wilson SW, Cooper JD, Russell C. A zebrafish model of CLN2 disease is deficient in tripeptidyl peptide 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation. Brain. 2013;136:1488–507.

16. Mirey H, Fabritius AL, Vesa J, Peltonen L. Data on characterizing the gene expression patterns of neuronal ceroid lipofuscinosis genes: CLN1, CLN2, CLN3, CLN5 and their association to interneuron and neurotransmitter markers: Parvalbumin and Somatostatin. Data in Brief. 2016;7:841–9.

17. Mole SE, Goyal S, Williams RE. The neuronal Ceroid Lipofuscinoses. In: Panayotopoulos CP, editor. Atlas of epilepsies. London: Springer; 2010. p. 1235–41.

18. Kashyap SS, Johnson JR, McCue HV, Chen X, Edmonds MJ, Ayala M, Graham ME, Jenn RC, Barclay JW, Burgoyne RD, Morgan A. Camorohabditis elegans dpy-14, the orthologue of the Drosophila gene mutated in adult onset neuronal ceroid lipofuscinosis, provides a new platform for neuroprotective drug screening and identifies a SB-21-independent action of resveratrol. Human Molecular Genetics. 2014;23:5916–27.

19. Cray D, Dragostin O, Dica A, Hoffman-Zacharska D, Gos M, Bastian AE, Gherghiceanu M, Rolfs A, Nahavandi N, Crau M, Iliescu C. Ret L-like onset in infantile neuronal ceroid lipofuscinoses (CLN7) caused by compound heterozygous mutation in the MFSD8 gene and review of the literature on clinical onset signs. Eur J Pediatr Neurol. 2015;19(1):78–86.

20. Ashkenazy H, Erez I, Marze E, Pupko T, Ben-Tal N. ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Res. 2010;38:W29–33.

21. Aiello C, Terracciano A, Simonati A, Discipolo G, Cannelli N, Claps D, Crow YJ, Bianchi M, Kitzmuller C, Longo D, Tavoni A. Mutations in MFSD8/CLN7 are a frequent cause of variant-late infantile neuronal ceroid lipofuscinosis. Hum Mutat. 2009;30(5):E50–40.

22. Sacco T, Mello M, Bechera EG, Davidovich L, Berretta A, Catania MV, Gecz J, Lalli E, Bardoni B. FRAXE-associated mental retardation protein (FMR2) is a RNA-binding protein with high affinity for G-quartet RNA forming structure. Nucleic Acids Research. 2009;37:1269–79.

23. Mondal K, Ramachandran D, Patel VC, Hagen KR, Bose P, Cutler DJ, Zwick ME. Excess variants in FMR2 detected by massively parallel sequencing of males with autism spectrum disorder. Hum Mol Genet. 2012;21(19):4354–66.

24. Weinsten E, Cui X, Simmons P, Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders. United States patent application US 12/842,678. 2010.

25. Todorova A, Litvinchenko I, Todorov T, Tincheva R, Avdijeva D, Tincheva S, Mitev V. A family with fragile X syndrome, Duchenne muscular dystrophy and ichthyosis transmitted by an asymptomatic carrier. Clin Genet. 2014; 85(3):286–9.

26. Sahoo T, Theisen A, Marble M, Tervo R, Rosenfeld JA, Torchia BS, Shaffer LG. Microdeletion of Xq28 involving the ME genes: Parvalbumin and Somatostatin. Data in Brief. 2016;8:741–742.

27. Kashyap SS, Johnson JR, McCue HV, Chen X, Edmonds MJ, Ayala M, Graham ME, Jenn RC, Barclay JW, Burgoyne RD, Morgan A. Camorohabditis elegans dpy-14, the orthologue of the Drosophila gene mutated in adult onset neuronal ceroid lipofuscinosis, provides a new platform for neuroprotective drug screening and identifies a SB-21-independent action of resveratrol. Human Molecular Genetics. 2014;23:5916–27.

28. Cray D, Dragostin O, Dica A, Hoffman-Zacharska D, Gos M, Bastian AE, Gherghiceanu M, Rolfs A, Nahavandi N, Crau M, Iliescu C. Ret L-like onset in infantile neuronal ceroid lipofuscinoses (CLN7) caused by compound heterozygous mutation in the MFSD8 gene and review of the literature on clinical onset signs. Eur J Pediatr Neurol. 2015;19(1):78–86.

29. Ashkenazy H, Erez I, Marze E, Pupko T, Ben-Tal N. ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Res. 2010;38:W29–33.

30. Aiello C, Terracciano A, Simonati A, Discipolo G, Cannelli N, Claps D, Crow YJ, Bianchi M, Kitzmuller C, Longo D, Tavoni A. Mutations in MFSD8/CLN7 are a frequent cause of variant-late infantile neuronal ceroid lipofuscinosis. Hum Mutat. 2009;30(5):E50–40.

31. Sacco T, Mello M, Bechera EG, Davidovich L, Berretta A, Catania MV, Gecz J, Lalli E, Bardoni B. FRAXE-associated mental retardation protein (FMR2) is a RNA-binding protein with high affinity for G-quartet RNA forming structure. Nucleic Acids Research. 2009;37:1269–79.

32. Mondal K, Ramachandran D, Patel VC, Hagen KR, Bose P, Cutler DJ, Zwick ME. Excess variants in FMR2 detected by massively parallel sequencing of males with autism spectrum disorder. Hum Mol Genet. 2012;21(19):4354–66.

33. Weinsten E, Cui X, Simmons P, Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders. United States patent application US 12/842,678. 2010.

34. Todorova A, Litvinchenko I, Todorov T, Tincheva R, Avdijeva D, Tincheva S, Mitev V. A family with fragile X syndrome, Duchenne muscular dystrophy and ichthyosis transmitted by an asymptomatic carrier. Clin Genet. 2014; 85(3):286–9.

35. Sahoo T, Theisen A, Marble M, Tervo R, Rosenfeld JA, Torchia BS, Shaffer LG. Microdeletion of Xq28 involving the FMR2 (FMR2) gene in two unrelated males with developmental delay. Am J Med Genet A. 2011;155(12):3110–5.

36. Santos CB, Lima C, Pimentel MM. A new PCR assay useful for screening of FRAXE/FMR2 mental impairment among males. Hum Mutat. 2001;18(2):157–62.